Aisa Pharma Reports Positive Phase II Data for AISA-021
Boston, Massachusetts, United States, November 9, 2026 Aisa Pharma, Inc. has announced additional clinical findings from its Phase II...
orphan drug designation
Advertisement
JCR Gains Japan Orphan Drug Designation for Givinostat
HYOGO, Japan — September 28, 2026 JCR Pharmaceuticals Co., Ltd. announced that Japan’s Ministry of Health, Labour and Welfare...
Leads Biolabs Gains Japan Orphan Drug Designation for Opamtistomig
NANJING, China — September 28, 2026 Leads Biolabs announced that opamtistomig (LBL-024), its investigational PD-L1/4-1BB bispecific antibody, has received...
Ocugen Gains Provisional Approval for OCU400 in The Bahamas
MALVERN, Pa. — September 25, 2026 Ocugen Inc. announced that its investigational modifier gene therapy OCU400 has received provisional...
Persevere Therapeutics Doses First Patient in MIROC-1
CHESTERBROOK, Pa. — September 24, 2026 Persevere Therapeutics, Inc. announced that the first patient has been enrolled and treated...
Advertisements
Beactica Advances BEA-17 Toward Glioblastoma Trials
Uppsala, Sweden, September 22, 2026 Beactica Therapeutics AB has announced the initiation of IND-enabling studies for BEA-17, its wholly...
Pharmazz Gains FDA Orphan Designation for Sovateltide in NHIE
WILLOWBROOK, Ill. — September 14, 2026 Pharmazz, Inc. announced that the U.S. Food and Drug Administration (FDA) Office of...
Lundbeck Gains FDA Orphan Drug Status for Asedebart
Copenhagen, Denmark, September 10, 2026 H. Lundbeck A/S has announced that the U.S. Food and Drug Administration (FDA) has...
SciSparc Pursues FDA Orphan Drug Designation for SCI-110 in Tourette Syndrome
Tel Aviv, Israel, September 2, 2026 SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. is pursuing U.S....
Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
Advertisement
